The metastatic potential of triple-negative breast cancer is decreased via caloric restriction-mediated reduction of the miR-17~92 cluster

Breast Cancer Research and Treatment

Volumn 146, Issue 1, 2014, Pages 41-50

  Jin, Lianjin ^a   Lim, Meng ^a   Zhao, Shuping ^b   Sano, Yuri ^a   Simone, Brittany A ^a   Savage, Jason E ^b   Wickstrom, Eric ^a   Camphausen, Kevin ^b   Pestell, Richard G ^a   Simone, Nicole L ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Caloric restriction; microRNA; miR 17 92 cluster; Radiation; Triple negative breast cancer

Indexed keywords

COLLAGEN TYPE 4; COLLAGEN TYPE 4 ALPHA 3; COMPLEMENTARY DNA; LAMININ; LAMININ ALPHA3; MICRORNA; MICRORNA 17; MICRORNA 20A; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3; UNCLASSIFIED DRUG; MESSENGER RNA; SCLEROPROTEIN;

3' UNTRANSLATED REGION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALORIC RESTRICTION; CANCER RADIOTHERAPY; COL4A1 GENE; COL4A3 GENE; COMPUTER MODEL; CONTROLLED STUDY; DOWN REGULATION; EXTRACELLULAR MATRIX; FEMALE; GENE; GENE CLUSTER; GENE EXPRESSION REGULATION; GENE ONTOLOGY; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GENETIC TRANSFECTION; HEK293 CELL LINE; HUMAN; HUMAN CELL; IN VIVO STUDY; IONIZING RADIATION; LAMA3 GENE; METASTASIS POTENTIAL; MICROARRAY ANALYSIS; MOLECULAR INTERACTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TIMP2 GENE; TIMP3 GENE; TRIPLE NEGATIVE BREAST CANCER; TUMOR REGRESSION; UPREGULATION; ANIMAL; BINDING SITE; CELL MOTION; CHEMISTRY; DISEASE MODEL; GENE EXPRESSION; GENETICS; METABOLISM; METASTASIS; MULTIGENE FAMILY; NUCLEOTIDE SEQUENCE; PATHOLOGY; SEQUENCE ALIGNMENT; TUMOR CELL LINE;

ANIMALS; BASE SEQUENCE; BINDING SITES; CALORIC RESTRICTION; CELL LINE, TUMOR; CELL MOVEMENT; DISEASE MODELS, ANIMAL; EXTRACELLULAR MATRIX PROTEINS; FEMALE; GENE EXPRESSION; HUMANS; MICE; MICRORNAS; MULTIGENE FAMILY; NEOPLASM METASTASIS; RADIATION, IONIZING; RNA, MESSENGER; SEQUENCE ALIGNMENT; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TISSUE INHIBITOR OF METALLOPROTEINASE-3; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84903743135     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-014-2978-7     Document Type: Article

References (38)

1. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA (2007) Triplenegative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13(15):4429-4434. doi:10.1158/1078-0432.ccr-06-3045 (Pubitemid 47219710)
2. Hernandez-Aya LF, Chavez-MacGregor M, Lei X, Meric-Bernstam F, Buchholz TA, Hsu L, Sahin AA, Do K-A, Valero V, Hortobagyi GN, Gonzalez-Angulo AM (2011) Nodal status and clinical outcomes in a large cohort of patients with triple-negative breast cancer. J Clin Oncol 29(19):2628-2634. doi:10.1200/jco.2010.32.1877
3. Foulkes WD, Smith IE, Reis-Filho JS (2010) Triple-negative breast cancer. N Engl J Med 363(20):1938-1948. doi:10.1056/NEJMra1001389
4. Pogoda K, Niwińska A, Murawska M, Pieńkowski T (2013) Analysis of pattern, time and risk factors influencing recurrence in triple-negative breast cancer patients. Med Oncol 30(1):1-8. doi:10.1007/s12032-012-0388-4
5. Montagna E, Maisonneuve P, Rotmensz N, Cancello G, Iorfida M, Balduzzi A, Galimberti V, Veronesi P, Luini A, Pruneri G, Bottiglieri L, Mastropasqua MG, Goldhirsch A, Viale G, Colleoni M (2013) Heterogeneity of triple-negative breast cancer: histologic subtyping to inform the outcome. Clin Breast Cancer 13(1):31-39. doi:10.1016/j.clbc.2012.09.002
6. Fujita T, Mizukami T, Okawara T, Inoue K, Fujimori M (2013) Identification of a novel inhibitor of triple-negative breast cancer cell growth by screening of a small-molecule library. Breast Cancer 1-10. doi:10.1007/s12282-013-0452-8
7. Metzger-Filho O, Tutt A, de Azambuja E, Saini KS, Viale G, Loi S, Bradbury I, Bliss JM, Azim HA, Ellis P, Di Leo A, Baselga J, Sotiriou C, Piccart-Gebhart M (2012) Dissecting the heterogeneity of triple-negative breast cancer. J Clin Oncol 30(15):1879-1887. doi:10.1200/jco.2011.38.2010
8. Duncan James S, Whittle Martin C, Nakamura K, Abell Amy N, Midland Alicia A, ZawistowskiJon S, Johnson Nancy L, Granger Deborah A, Jordan Nicole V, Darr David B, Usary J, Kuan P-F, Smalley David M, Major B, He X, Hoadley Katherine A, Zhou B, Sharpless Norman E, Perou Charles M, Kim William Y, Gomez Shawn M, Chen X, Jin J, Frye Stephen V, Earp HS, Graves Lee M, Johnson Gary L (2012) Dynamic reprogramming of the kinome in response to targeted mek inhibition in triple-negative breast cancer. Cell 149(2):307-321. doi:10.1016/j.cell.2012.02. 053
9. Yunokawa M, Koizumi F, Kitamura Y, Katanasaka Y, Okamoto N, Kodaira M, Yonemori K, Shimizu C, Ando M, Masutomi K, Yoshida T, Fujiwara Y, Tamura K (2012) Efficacy of everolimus, a novel mTOR inhibitor, against basal-like triple-negative breast cancer cells. Cancer Sci 103(9):1665-1671. doi:10.1111/j.1349-7006.2012.02359.x
10. Song H, Hedayati M, Hobbs RF, Shao C, Bruchertseifer F, Morgenstern A, DeWeese TL, Sgouros G (2013) Targeting aberrant DNA double strand break repair in triple negative breast cancer with alpha particle emitter radiolabeled anti-EGFR antibody. Mol Cancer Ther. doi:10.1158/1535-7163.mct-13-0108
11. Ibrahim YH, García-García C, Serra V, He L, Torres-Lockhart K, Prat A, Anton P, Cozar P, Guzmán M, Grueso J, Rodríguez O, Calvo MT, Aura C, Díez O, Rubio IT, Pérez J, Rodón J, Cortés J, Ellisen LW, Scaltriti M, Baselga J (2012) PI3 K Inhibition Impairs BRCA1/2 Expression And Sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. Cancer Discov 2(11):1036-1047. doi:10.1158/2159- 8290.cd-11-0348
12. Al-Ejeh F, Shi W, Miranda M, Simpson PT, Vargas AC, Song S, Wiegmans AP, Swarbrick A, Welm AL, Brown MP, Chenevix-Trench G, Lakhani SR, Khanna KK (2013) Treatment of triplenegative breast cancer using anti-EGFR-directed radioimmunotherapy combined with radiosensitizing chemotherapy and PARP inhibitor. J Nucl Med 54(6):913-921. doi:10.2967/jnumed.112.111534
13. De Lorenzo MS, Baljinnyam E, Vatner DE, Abarzúa P, Vatner SF, Rabson AB (2011) Caloric restriction reduces growth of mammary tumors and metastases. Carcinogenesis 32(9):1381-1387. doi:10.1093/carcin/bgr107
14. Phoenix K, Vumbaca F, Fox M, Evans R, Claffey K (2010) Dietary energy availability affects primary and metastatic breast cancer and metformin efficacy. Breast Cancer Res Treat 123(2):333-344. doi:10.1007/s10549-009-0647-z
15. Colman RJ, Anderson RM, Johnson SC, Kastman EK, Kosmatka KJ, Beasley TM, Allison DB, Cruzen C, Simmons HA, Kemnitz JW, Weindruch R (2009) Caloric restriction delays disease onset and mortality in rhesus monkeys. Science 325(5937):201-204. doi:10.1126/science.1173635
16. Blagosklonny MV (2010) Calorie restriction: decelerating mTOR-driven aging from cells to organisms (including humans). Cell Cycle 9(4):683-688
17. Saleh AD, Simone BA, Palazzo J, Savage JE, Sano Y, Dan T, Jin L, Champ CE, Zhao S, Lim M, Sotgia F, Camphausen K, Pestell RG, Mitchell JB, Lisanti MP, Simone NL (2013) Caloric restriction augments radiation efficacy in breast cancer. Cell Cycle 12(12):8
18. Zambon AC, Gaj S, Ho I, Hanspers K, Vranizan K, Evelo CT, Conklin BR, Pico AR, Salomonis N (2012) GO-Elite: a flexible solution for pathway and ontology over-representation. Bioinformatics 28(16):2209-2210. doi:10.1093/bioinformatics/bts366
19. Reiner A, Yekutieli D, Benjamini Y (2003) Identifying differentially expressed genes using false discovery rate controlling procedures. Bioinformatics 19(3):368-375. doi:10.1093/bioinfor matics/btf877
20. Farazi TA, Horlings HM, ten Hoeve JJ, Mihailovic A, Halfwerk H, Morozov P, Brown M, Hafner M, Reyal F, van Kouwenhove M, Kreike B, Sie D, Hovestadt V, Wessels LFA, van de Vijver MJ, Tuschl T (2011) MicroRNA sequence and expression analysis in breast tumors by deep sequencing. Cancer Res 71(13):4443-4453. doi:10.1158/0008-5472.can-11-0608
21. Dews M, Homayouni A, Yu D, Murphy D, Sevignani C, Wentzel E, Furth EE, Lee WM, Enders GH, Mendell JT, Thomas-Tikhonenko A (2006) Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. Nat Genet 38(9):1060-1065. http://www.nature.com/ng/journal/v38/n9/suppinfo/ng1855-S1.html (Pubitemid 44325933)
22. Volinia S, Galasso M, Sana ME, Wise TF, Palatini J, Huebner K, Croce CM (2012) Breast cancer signatures for invasiveness and prognosis defined by deep sequencing of microRNA. Proc Natl Acad Sci 109(8):3024-3029. doi:10.1073/pnas.1200010109
23. Volinia S, Calin GA, Liu C-G, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, Prueitt RL, Yanaihara N, Lanza G, Scarpa A, Vecchione A, Negrini M, Harris CC, Croce CM (2006) A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 103(7):2257-2261. doi:10.1073/pnas.0510565103 (Pubitemid 43271657)
24. Mendell JT (2008) miRiad roles for the miR-17-92 cluster in development and disease. Cell 133(2):217-222. doi:10.1016/j.cell.2008.04.001
25. O'Donnell KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT (2005) c-Myc-regulated microRNAs modulate E2F1 expression. Nature 435(7043):839-843. http://www.nature.com/nature/jour nal/v435/n7043/suppinfo/nature03677-S1.html (Pubitemid 40839736)
26. Ivanovska I, Ball AS, Diaz RL, Magnus JF, Kibukawa M, Schelter JM, Kobayashi SV, Lim L, Burchard J, Jackson AL, Linsley PS, Cleary MA (2008) MicroRNAs in the miR-106b family regulate p21/CDKN1A and promote cell cycle progression. Mol Cell Biol 28(7):2167-2174. doi:10.1128/mcb.01977-07 (Pubitemid 351429964)
27. Molitoris JK, McColl KS, Distelhorst CW (2011) Glucocorticoidmediated repression of the oncogenic microRNA cluster miR- 17-92 contributes to the induction of bim and initiation of apoptosis. Mol Endocrinol 25(3):409-420. doi:10.1210/me.2010-0402
28. Cascione L, Gasparini P, Lovat F, Carasi S, Pulvirenti A, Ferro A, Alder H, He G, Vecchione A, Croce CM, Shapiro CL, Huebner K (2013) Integrated MicroRNA and mRNA signatures associated with survival in triple negative breast cancer. PLoS One 8(2):e55910. doi:10.1371/journal.pone.0055910
29. John-Aryankalayil M, Palayoor ST, Makinde AY, Cerna D, Simone CB 2nd, Falduto MT, Magnuson SR, Coleman CN (2012) Fractionated radiation alters oncomir and tumor suppressor miRNAs in human prostate cancer cells. Radiat Res 178(3):105-117
30. Zhang X, Yu H, Lou JR, Zheng J, Zhu H, Popescu N-I, Lupu F, Lind SE, Ding W-Q (2011) MicroRNA-19 (miR-19) regulates tissue factor expression in breast cancer cells. J Biol Chem 286(2):1429-1435. doi:10.1074/jbc.M110.146530
31. Dews M, Fox JL, Hultine S, Sundaram P, Wang W, Liu YY, Furth E, Enders GH, El-Deiry W, Schelter JM, Cleary MA, Thomas-Tikhonenko A (2010) The myc-miR-17-92 axis blunts TGFb signaling and production of multiple TGFb-dependent antiangiogenic factors. Cancer Res 70(20):8233-8246. doi:10.1158/0008-5472.can-10-2412
32. Curran CS, Keely PJ (2013) Breast tumor and stromal cell responses to TGF-b and hypoxia in matrix deposition. Matrix Biol 32(2):95-105. doi:10.1016/j.matbio.2012.11.016
33. DeClerck YA, Mercurio AM, Stack MS, Chapman HA, Zutter MM, Muschel RJ, Raz A, Matrisian LM, Sloane BF, Noel A, Hendrix MJ, Coussens L, Padarathsingh M (2004) Proteases, extracellular matrix, and cancer: a workshop of the path B study section. Am J Pathol 164(4):1131-1139. doi:10.1016/S0002-9440(10)63200-2 (Pubitemid 38387779)
34. Carey L, Winer E, Viale G, Cameron D, Gianni L (2010) Triplenegative breast cancer: disease entity or title of convenience? Nat Rev Clin Oncol 7(12):683-692. http://www.nature.com/nrcli nonc/journal/v7/n12/suppinfo/ nrclinonc.2010.154-S1.html
35. Lee C, Raffaghello L, Brandhorst S, Safdie FM, Bianchi G, Martin-Montalvo A, Pistoia V, Wei M, Hwang S, Merlino A, Emionite L, de Cabo R, Longo VD (2012) Fasting cycles retard growth of tumors and sensitize a range of cancer cell types to chemotherapy. Sci Transl Med 4(124):124ra127. doi:10.1126/scitranslmed. 3003293
36. Lee C, Safdie FM, Raffaghello L, Wei M, Madia F, Parrella E, Hwang D, Cohen P, Bianchi G, Longo VD (2010) Reduced levels of IGF-I mediate differential protection of normal and cancer cells in response to fasting and improve chemotherapeutic index. Cancer Res 70(4):1564-1572. doi:10.1158/0008-5472.can- 09-3228
37. Longo VD, Ellerby LM, Bredesen DE, Valentine JS, Gralla EB (1997) Human Bcl-2 reverses survival defects in yeast lacking superoxide dismutase and delays death of wild-type yeast. J Cell Biol 137(7):1581-1588. doi:10.1083/jcb.137.7. 1581 (Pubitemid 27282238)
38. Wei M, Fabrizio P, Hu J, Ge H, Cheng C, Li L, Longo VD (2008) Life span extension by calorie restriction depends on Rim15 and transcription factors downstream of Ras/PKA, Tor, and Sch9. PLoS Genet 4(1):e13. doi:10.1371/journal. pgen.0040013